Home > Riviste > Panminerva Medica > Fascicoli precedenti > Articles online first > Panminerva Medica 2017 Apr 11

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

PANMINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

Panminerva Medica 2017 Apr 11

DOI: 10.23736/S0031-0808.17.03321-3

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Heart failure and role of circulating MMP-2 and MMP-9

Jana RADOSINSKA 1, 2 , Miroslav BARANCIK 2, Norbert VRBJAR 2

1 Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovak Republic; 2 Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic


PDF  


The myocardial extracellular matrix (ECM) is the dynamic environment that is fundamental for the structural and physiological homeostasis of the heart. Alterations in ECM homeostasis may lead to diastolic or systolic dysfunction and consequent development of heart failure (HF). For degradation of ECM, matrix metalloproteinases (MMPs) are responsible. To the most frequently analyzed MMPs in relation to HF syndrome belong MMP-2 and MMP-9. This review summarizes the recent knowledge concerning the role of circulating MMP-2 and MMP-9 (i.e. those that can be determined in blood plasma or serum) in HF, based primarily on papers from human studies. Majority of studies enrolling the higher count of participants suggested that the state of active myocardial remodeling is accompanied by enhanced activation of MMP-2 and MMP-9 and may be also represented by changes in their circulating concentrations. Their levels may be a useful marker for the identification of patients at risk for HF development and poor outcome by themselves, or at the very least as a components of multimarker approach. At the same time MMP-2 and MMP-9 circulating levels can serve as indicators of efficiency of the therapy provided to HF patients, as well as for identification of patients who could profit from particular therapeutic intervention via modification of MMP pathway.


KEY WORDS: Matrix Metalloproteinase 2 - Matrix Metalloproteinase 9 - Heart Failure - Myocardial Remodeling - Biomarkers

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

jana.radosinska@fmed.uniba.sk